Roche Initiates Large-Scale Screening Study for Alzheimer's Disease to Identify Eligible Participants for Interventional Trials

Data from the Drug Clinical Trial Registration and Information Disclosure Platform shows that the master screening study to identify individuals with potential eligibility for Alzheimer's disease research based on biomarker status and cognitive assessment, conducted by F. Hoffmann-La Roche Ltd/Roche (China) Investment Co., Ltd./1) Genentech, Inc.; 2) F. Hoffmann-La Roche AG, has been initiated. The clinical trial registration number is CTR20253843, and the initial information disclosure date was October 14, 2025.

The drug's dosage form, usage, and dosage information have not been disclosed yet. The purpose of this trial is to identify individuals with potential eligibility for Alzheimer's disease research through biomarker status and cognitive assessment.

This drug is a biologic, indicated for Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder, with main symptoms including memory loss, cognitive dysfunction, etc. Diagnosis relies on neuropsychological tests, imaging examinations, etc.

The primary endpoint indicators of this trial include determining the biomarkers and cognitive status of subjects who may be in the early stages of AD dementia or at risk of AD dementia enrolled in this study, as well as their potential eligibility to participate in Roche's interventional AD studies; secondary endpoint indicators have not been filled in yet.

Currently, the trial status is ongoing (recruiting), with a target enrollment of 1,100 participants in China and 13,000 globally; 28 participants have been enrolled in China.

Risk Warning: The market has risks, and investments should be made with caution. This article is automatically published by an AI large model based on a third-party database. Any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, or any form of expression, etc.) is for reference only and does not constitute personal investment advice. Due to issues such as the quality of the third-party database, we are unable to verify or confirm the authenticity and completeness of the data. Therefore, the content of this article may contain inaccuracies, incompleteness, or misleading information. Please refer to official company announcements for specifics. If you have any questions, please contact biz@staff.sina.com.cn.

Editor: Xiaolang Express